[Viewpoint] Hepatitis A prevention in the USA depends on routine universal childhood vaccination
This is an editorial summary of research originally reported by The Lancet. ProductSafer does not claim ownership of the underlying research. All intellectual property belongs to the original publishers.
On Jan 5, 2026, the Acting Director of the US Centers for Disease Control and Prevention (CDC) signed a decision memorandum from the heads of the National Institutes of Health, the Centers for Medicare & Medicaid Services, and the US Food and Drug Administration, which removed vaccines against meningococcal disease, influenza, COVID-19, hepatitis A, and hepatitis B, including the birth dose, as routinely recommended vaccines for all children.1 Instead, except for certain groups at high risk, the
# Editorial Summary
In early 2026, U.S. health authorities made a significant policy shift by removing several vaccines—including hepatitis A protection—from the list of routine vaccines recommended for all children. Under the new guidance, hepatitis A vaccination is now primarily recommended only for children considered at higher risk rather than as a universal childhood vaccine. This change marks a departure from decades of public health strategy aimed at preventing hepatitis A outbreaks across the general population.
Hepatitis A is a viral infection that affects the liver and spreads through contaminated food and water or close contact with infected individuals. While most people recover fully from hepatitis A, the infection can cause severe illness, particularly in older adults and people with existing liver disease. Before hepatitis A vaccine became a routine childhood immunization, the virus caused thousands of cases annually in the United States. The vaccine has been credited with dramatically reducing hepatitis A cases over the past two decades.
The rationale behind removing hepatitis A from universal vaccination recommendations reflects a shift in risk assessment by federal health agencies including the CDC, FDA, and NIH. However, public health experts have expressed concern that moving away from universal childhood vaccination could allow hepatitis A to resurface in communities, particularly among unvaccinated children and vulnerable populations who may not qualify as "high risk" under the new guidelines.
For parents and caregivers, it's important to discuss hepatitis A vaccination with your child's doctor, even if it's no longer automatically recommended. Ask whether your child should receive the vaccine based on your family's circumstances, travel plans, or community health status. If you have questions about whether hepatitis A protection is right for your child, your healthcare provider can help you make an informed decision based on current risk factors in your area.
Read the full report at the original source
The LancetWas this finding useful?